ArticleNeurology(R) neuroimmunology & neuroinflammation2026
Spinal Cord Leptomeningeal Enhancement as a Marker of Extensive Spinal Cord Involvement in Children With MOGAD.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding Evidence of Leptomeningeal Involvement in MOGAD and Its Relevance to Its Pathophysiology.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSpinal cord leptomeningeal enhancement (LME) can be observed in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and with seronegative myelitis. We investigated whether the presence of spinal cord LME in MOGAD and seronegative myelitis is associated with distinct clinical, CSF, and MRI findings.
methodsStudy participants were identified among the 490 children and adolescents recruited to the Canadian Pediatric Demyelinating Disease study following an incident attack of CNS demyelination. Inclusion criteria for this study were: (1) evidence of spinal cord lesions on MRI, (2) available postgadolinium MRI sequences, and (3) available MOG and aquaporin-4 (AQP4) antibody results. None of the AQP4 antibody-positive participants met our inclusion criteria and only 1 participant with multiple sclerosis exhibited LME. We therefore focused the study on children with MOGAD and seronegative myelitis and compared the clinical, CSF, and MRI features between participants with and without LME.
resultsOur cohort included 33 participants with MOGAD (median age 5.9 years, 55% women) and 45 with seronegative myelitis (median age 11.9 years, 33% women). Spinal cord LME was detected in 20/33 (61%) participants with MOGAD and 14/45 (31%) with seronegative myelitis. Among children with MOGAD, those with LME were more likely than those without LME to have longitudinally extensive myelitis ([LETM], 19/20 vs 8/13, DISCUSSION: The presence of spinal cord LME is associated with more extensive spinal cord abnormalities on MRI in children with MOGAD and to a lesser extent in those with seronegative myelitis. The biological underpinnings of this finding and its clinical implications should be assessed in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.